Mechanisms of hypocomplementemia in glomerulonephritis  by West, Clark D. et al.
Kidney International, Vol.3 (l973),p. 116—125
Mechanisms of hypocomplementemia in glomerulonephritis
CLARK D. WEST, EDWARD J. RULEY, JUDITH FORRISTAL and NEIL C. DAVIS
Children's Hospital Research Foundation and the Department of Pediatrics, University of Cincinnati
College of Medicine, Cincinnati, Ohio
Although Ounn [1] in 1914 first observed the low serum
complement levels in acute post-streptococcal nephritis, it
was Kellett [2] who in 1935 first hypothesized that the by-
pocomplementemia was the result of an antigen-antibody
reaction occurring in the tissues. Observing three patients
with low serum complement levels at the onset of acute
nephritis, he stated "I suggest that acute glomerulonephritis
may be a condition, essentially generalized, resulting from
reaction between antibodies elaborated by the body and
toxins elaborated by the organisms that played a part in the
original infection, the toxins having been fixed in some way
to the tissue cells, and more particularly to those of the
kidney ... ." Another24 years passed before it was suggested
that the reaction of complement with immune complexes,
rather than toxins, produced the nephritis. Schwab and
associates [3J, studying experimental hypersensitivity in
rabbits, suggested in 1950 that fixed complement played an
active role in the production of renal cellular damage during
the in vivo antigen-antibody reaction which occurs after the
injection of a foreign protein. This concept was obviously
greatly strengthened and made applicable to human disease
by the demonstration of Lachmann and associates [4] that
with labeled antibody the third component of complement
could be detected in the renal glomeruli in acute glomeru-
lonephritis and lupus nephritis as well as in certain other
nephritides.
The great advances in understanding of complement and
of nephritis which have occurred in recent years have
allowed further exploration of these concepts. With time
paradoxes have emerged. Complement can be demonstrated
in the glomeruli in nephritides which are not associated
with a reduction in serum complement. Complement pro-
files have shown that in some hypocomplementemic ne-
phritides, certain components are in normal concentration
while in others, all components tend to be low [5—8]. In
hypocomplementemic patients with membrano-proliferative
nephritis a factor has been found in the serum which appears
to be responsible for the hypocomplementemia [9]. Recent
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studies have indicated that the serum from patients with
systemic lupus erythematosus and active nephritis often
contains factors directly reacting with Clq [10]. It becomes
apparent from these observations that in these two forms
of nephritis, at least, the hypocomplementemia could be the
result almost entirely of a complement reaction occurring
in the circulation rather than, as Kellett [2] implied, in the
kidneys. Supporting this concept is the observation that in
membrano-proliferative nephritis, hypocomplementemia
continues in the absence of kidneys [11]. A problem yet to
be solved is how the mechanism producing the hypocom-
plementemia relates to that producing the nephritis. This is
an especially difficult question in acute post-streptococcal
and membrano-proliferative nephritis.
In this paper some of the recent observations concerning
the origin of the hypocomplementemia in lupus nephritis,
acute post-streptococcal glomerulonephritis and membrano-
proliferative glomerulonephritis will be summarized and
further observations added. The potential for greater under-
standing in this area has recently increased as a result of the
demonstration of an alternate pathway of complement acti-
vation which can be initiated in vitro by a number of sub-
stances and has as its primary target the third component
of complement [12]. Despite this advance there are still
many gaps in our comprehension of some of the intimate
details of the mechanism responsible for the hypocomple-
mentemia and, more particularly, of the factors responsible
for the glomerular inflammation.
Mechanisms of complement activation
Until recently only one pathway for activation of com-
plement had been described [13]. In this classical pathway,
gamma globulin, altered either by its reaction with anti-
body or by aggregation, initiates the reaction by producing
a binding site for Clq, thus activating Cl. The various
immunoglobulins differ in their efficiency in activating Cl.
1gM is considerably more effective than IgG and IgA
lacks the ability. Of the sub-types of IgG, IgG1 and IgG3
react readily with Clq whereas IgG2 reacts poorly and
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IgG4 does not usually react. Activation of complement by
this means involves all eleven components; addition of an
immune complex consisting of BSA-antiBSA to fresh
guinea pig serum in vitro affects the levels of all comple-
ment components as measured by hemolytic assay [14].
Of great potential importance is the recently discovered
alternate pathway of complement activation [12]. This
pathway bypasses the first three reacting components, CI,
C4 and C2, [12, 14], and can be activated in the absence of
altered IgG or 1gM. Complex polysaccharides such as
zymosan, inulin, lipopolysaccharide endotoxin and agar, as
well as altered IgA and IgG, can, on addition to fresh human
serum in vitro, initiate the alternate pathway. By this
pathway consumption of C3—9 is initiated with generation
of biologically active complement products such as ana-
phylotoxins and chemotactic factors. It has been known
since the studies of Pillemer [15, 16] that properdin is in-
volved when the pathway is activated by complex poly-
saccharides. The properdin complexes to the particulate
polysaccharide but its role in initiating the reaction is not
clear. In the alternate pathway the immediate C3 activating
agent is the C3 activator, a protein with a gamma mobility
formed as a breakdown product of the C3 proactivator [12].
The C3 proactivator is a beta globulin and, with activation
of the alternate pathway, a shift in the mobility of the C3
proactivator from its typical beta position to the gamma
position of the C3 activator can be readily demonstrated
using monospecific antiserum. The C3 proactivator has a
molecular weight of 80,000 and has also been designated
glycine-rich beta globulin [17] and properdin factor B [181.
Heating serum to 50° for 30 minutes inactivates the pro-
activator and also renders its antigenic determinants in-
capable of reacting with antibody. The splitting of the
proactivator to form the C3 activator is a function of C3
proactivator convertase, found by Müller-Eberhard and
Götze [19] to be a 3S alpha globulin. Their studies indicated
that the activity of C3 proactivator convertase in normal
human serum required the presence of an intermediate
breakdown product of C3 which could be isolated from
outdated plasma and was tentatively identified as C3b. The
mechanism by which C3b is formed by the polysaccharides
or altered immunoglobulins which initiate the alternate
pathway is, however, obscure. If C3b is involved, there is
obviously a potential for a positive feedback mechanism
since C3b is transiently formed by the action of C3 activator
on C3.
The nephritis of systemic lupus erythematosus
As is well known, nephritis may occur very early in the
course of systemic lupus erythematosus or it may supervene
at any point in the course. In a high proportion of the cases,
active nephritis is accompanied by hypocomplementemia
[201. Two observations indicate that complement activation
in this disease occurs, at least in part, by the classical path-
way. First, it was shown some time ago by Gewurz et al
[6] that in contrast to other nephritides, the serum levels of
the first four reacting components, Cl, C4, C2 and C3,
measured by the hemolytic method, are in reduced concen-
tration when the nephritis is active. These observations
have been supported by observations of others using both
hemolytic and immunologic methods for the measurement
of complement components [5, 7, 8]. With therapy em-
ploying steroid and immunosuppressive agents, the con-
centrations rise into the normal range. In some patients the
rise in C4 is slow; the concentration of this component may
remain low for some time after the levels of the others have
returned to normal [5].
A second observation indicating classical pathway acti-
vation is that of Agnello, Winchester and Kunkel [10] and
Agnello et al [21] demonstrating that in the serum of
patients with active lupus nephritis, serum factors can be
demonstrated which react with Clq by double diffusion in
agar. This not only indicates that the reaction starts with
Cl but also that there is at least the potential in these pa-
tients for the complement reaction responsible for the hypo-
complementemia to occur in the circulation. These workers
described complement reactive factors of high molecular
weight which were closely associated with cryoglobulins.
They have yet to be identified but appeared to react with
both Clq and rheumatoid factors and were usually asso-
ciated with overt lupus nephritis with typical morphology
by light and immunofluorescence microscopy. In several
patients rheumatoid factor and in all, 1gM was identifiable
in the glomeruli by immunofluorescence. In contrast, a
second group of patients had Clq reactive material with a
sedimentation constant of 7S or lower. These patients had
severe hypocomplementemia but tended to have a much less
severe nephritis than those with circulating high molecular
weight complexes. Also by immunofluorescence, IgG and
C3 were not present in the typical pattern in the glomeruli
but were confined to deposits in the mesangium. A third
group of patients had a mixture of high and low molecular
weight Clq precipitable material. These patients had typical
lupus nephritis as did those who had only 19S material.
Not only do these studies provide evidence of classical
pathway activation and of circulating complement reactive
material but they also suggest that the complement reactive
material present in the circulation is also present in the
kidney and is the material visualized in the kidney by im-
munofluorescence. Thus, 1gM and rheumatoid factor could
usually be found in the glomeruli in the cases of lupus
nephritis with l9S complexes and could not be found in
cases where the complexes were 7S. In one case studied by
Agnello et al [21], fluorescein-labeled antisera with idio-
typic specificity for the patient's rheumatoid factor was
found to produce fluorescence of the patient's glomeruli but
not the glomeruli of other patients who had circulating
complexes containing rheumatoid factors.
The observation with respect to the dependence of the
development of nephritis on the size of the complement
reactive material has a parallel in the observations of serum
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sickness in rabbits by Cochrane and Hawkins [22] and
Cochrane [23]. A few animals injected with foreign pro-
tein formed circulating 7S immune complexes; in these
animals proteinuria did not occur and immunofluorescent
studies showed no deposits in vessel walls. The animals
did, however, have a depression of serum complement.
Animals forming complexes with sedimentation constants
greater than 19S on the other hand had a definite nephritis
with hypocomplementemia and complexes could be de-
monstrated in vessel walls by immunotluorescence. Thus
the animals segregated out into two groups as did the
patients with lupus nephritis described by Agnello et al [21].
In both the animals and the patients it would appear that
the character of the complement reactive material in the
circulation correlates with the deposits visualized in the
glomeruli by immunofluorescence.
Although the presence of Clq reactive material in the
plasma and the characteristics of the complement profile
are strong evidence for classical pathway activation in lupus
nephritis, neither observation rules out simultaneous alter-
nate pathway activation. Two points favor simultaneous
alternate pathway activation. First, as noted in Fig. 1 the
hypocomplementemia of active lupus nephritis is accom-
panied by reduced serum levels of C3 proactivator. The
patient whose data is depicted in Fig. 1 had a moderately
severe lupus nephritis with elevation of the BUN to 95
mg/l00 ml and the pattern of glomerular fluorescence of
the renal biopsy was typical of patients with complexes of
1 9S or greater [21]. In this patient the C3 proactivator levels
reached a nadir of 23 % of the average normal. The reason
for the lowest levels occurring some time after the serum
complement levels had fallen is obscure. Urinary loss as a
cause of the low C3 proactivator levels is possible insofar as
Fig. 1. Changes in serum C3, C3 proactivotor and C4 levels in the
course of lupus nephritis. The levels of C3 and C4 are measured
by the immunoelectrophoretic-precipitin method and C3 pro-
activator by radial immunodiffusion. The dashed line indicates
the lower limit of the normal range for all three proteins.
this patient had a nephrotic syndrome with total serum pro-
tein dropping to 4.5 g/100 ml and serum albumin to 2.5
g/l00 ml. However, in other patients with normocomple-
mentemic chronic glomerulonephritis and hypoproteinemia
and nephrotic syndrome more severe than in this patient,
C3 proactivator levels have been normal.
The second point in favor of alternate pathway activation
in lupus nephritis is the observation that incubation of the
complement reactive cryoprecipitate of lupus serum with
normal serum at 370 C results in a shift of the arc produced
by monospecific antiserum to the C3 proactivator from a
beta to a gamma mobility within 30 minutes. The shift is
the same as that which occurs when zymosan and inulin are
incubated with normal serum [12]. This observation suggests
that the circulating complexes can potentially activate the
complement system by the alternate as well as the classical
pathway and that activation can occur in the circulation.
The observations obviously do not rule out activation by
complexes deposited in glomerular capillary walls which are
in contact with circulating plasma.
In summary, the hypocomplementemia in lupus nephritis
is produced by circulating complement reactive complexes
which appear to be identical to those deposited in the renal
glomeruli. Present data indicate that these complexes acti-
vate the complement system through the classical pathway
and also through the alternate pathway. Iiypocomplemen-
lemia is probably in large part a result of activation of both
pathways in the circulation but activation by complexes
deposited in glomerular and other capillary walls may also
be occurring. The severity of the nephritis appears to be a
function, at least in part, of the size of the circulating com-
plement reactive complexes.
Membrano-proliferative nephritis
Hypocomplementemia is a frequent accompaniment of
membrano-proliferative nephritis in children but is less
frequently observed in adults [24]. No relationship has
been demonstrated between complement levels and progress
of the disease [24—26] in contrast to the close relationship
between low complement levels and disease activity in
lupus nephritis.
In membrano-proliferative nephritis the complement
profile gives strong evidence of an alternate pathway
mechanism; the three early reacting components are in
normal concentration whereas C3 may be markedly
reduced [6—8]. There is also evidence that components
reacting after C3 are in reduced concentraticn in membrano-
proliferative nephritis. As may be seen in Fig. 2, CS levels,
measured immunochemically, are frequently low when C3
is low. In addition, Thompson has observed that the
functional activity of C6 and C7 may also be reduced in
these patients [27]. These observations indicate that, as
with in vitro alternate pathway activation [14], the reaction
in viva not only breaks down C3 but also activates it with
activation in turn of late reacting components. The factor
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responsible for this distinctive complement profile may be
demonstrated by mixing serum from a patient with mem-
brano-proliferative nephritis (MPS) with normal serum
(NHS); after 20 minutes of incubation at 37 °C, up to
80% of the C3 in the mixture may be broken down to
fllA and alpha 2D [9, 28]. This reaction is Mg + dependent
and occurs without participation of Cl, C4 and C2. The
factor has been designated the C3 nephritic factor (C3NeF).
Because C3 breakdown did not occur when C3 was added
as a euglobulin fraction of NHS to MPS, the assumption
was made that a pseudoglobulin cofactor must be present
before C3NeF would cause cleavage of C3. It was assumed
that in vivo when C3NeF is demonstrable, the C3NeF
cofactor is absent or present in very low concentration [26].
Recent studies in this laboratory (Ruley, E. J., Forristal, J.,
Davis, N. C., Andres, C. and West, C. D., in manuscript)
have furnished additional evidence that C3NeF activates
the alternate pathway by demonstrating that the C3 pro-
activator is intimately involved in the reaction. Elimination
of the C3 proactivator from reaction mixtures containing
ncphritic and normal serum blocked C3 breakdown by
the C3NeF reaction. In these studies, the C3 proactivator
was removed from the serum either by equivalence absorp-
tion using a monospecific antiserum to C3 proactivator
(Behringwerke) or was inactivated by heating the serum
to 50 °C for 30 minutes. When MPS was so treated and
then mixed with untreated NHS, C3 breakdown occurred
as usual, indicating that removal or inactivation of C3
proactivator did not affect the C3 nephritic factor. How-
ever, if the C3 proactivator in NHS was eliminated or
inactivated, no C3 breakdown occurred after MPS was
added. If purified C3 proactivator was added to the mixture,
the expected C3 breakdown occurred.
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in these studies, measurement of C3 proactivator levels
in patients with membrano-proliferative nephritis gave
evidence that the proactivator was also involved in the
in vivo nephritic factor reaction. In specimens of MPS
from patients with reduced C3 levels, C3 proactivator
levels were frequently found to be reduced. The levels
showed a rough inverse correlation with C3NeF levels. In
specimens in which C3NeF was present in high concentra-
tion, C3 proactivator levels, measured by radial immuno-
diffusion, were definitely reduced, whereas in specimens
of MPS in which C3NeF was not demonstrable or present
in only small amounts, C3 proactivator levels were at the
lower limit of the normal range.
Further evidence of alternate pathway activation by
C3NeF was provided by the observation that C3NeF
caused a shift in the electrophoretic mobility of the C3
proactivator to that characteristic of the C3 activator.
Thus, when incubated mixtures of MPS and NHS were
electrophoresed in agar and reacted with monospecific
antiserum to the C3 proactivator, the precipitin arc was
in a gamma position as compared to the beta position
prior to incubation. The shift was the same as that seen
after incubation of NHS with zymosan or inulin. It did
not occur in mixtures of normal serum or mixtures contain-
ing MPS to which EDTA was added.
Measurements of C3 breakdown in mixtures containing
MPS to which purified C3 proactivator, purified C3 and
NHS had been added in various combinations gave some
insight into in vivo complement breakdown. The extent of
breakdown appeared to be a function of the C3NeF, C3
proactivator and C3 levels in the mixtures although a
contribution of other as yet unidentified factors necessary
for the C3NeF system cannot be ruled out. These unidenti-
fied factors would have been contributed by the MPS,
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present in all the mixtures. A previous study [28] indicated
that the extent of C3 breakdown depends on the C3
x concentration in the mixture. Thus in mixtures with initial
10 I C3 concentration in the range normally present in plasma
(22 to 50 units of B antigen/mI), extensive C3 breakdown
8 occurred which was linearly related to the C3NeF con-
x x x x centration in the mixture. Although not measured, it can
x x be assumed that in these experiments the concentration of
the C3 proactivator was in the normal range and constant.
At low C3 concentrations (9 units of B antigen/mi), C3
4 breakdown was slight and that which did occur was poorly
correlated with the C3NeF concentration. More recent
studies have indicated that when the C3 in the mixture,
2 provided by purified C3, is in a concentration at the lower
• limit of the normal range (about 20 units/ml) and the levels
0 of C3NeF and proactivator are approximately 25% of
0 20 40 60 80 100 120 140 those present in rico, C3 breakdown does not occur. With
the C3 concentration remaining in the same range, increas-
ing the concentrations of C3NeF and C3 proactivator to
50 and 75% of those present in vivo resulted in significant
breakdown. These results are not in agreement with
conclusions derived from earlier studies [9, 28]. As noted
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Fig. 2. Serum C3 levels plotted versus C5 levels for patients with
membrano-proliferative and acute post-streptococcal glomerulone-
phritis. Both proteins were measured by the immunoelectro-
phoretic-precipitin method.
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above, it was previously felt that the concentration of
eofactor was too low in MPS to support C3 breakdown
since C3 breakdown did not occur on addition of euglobulin
to MPS. These observations were made, however, on
reaction mixtures in which C3NeF and C3 proactivator
levels were 25% of those present in viva. The newer observ-
ations showing breakdown occurring as C3NeF and
proactivator levels approach those present in viva might
suggest that accelerated C3 breakdown is always occurring
in viva. However, it should be noted that the in vitro
conditions of these experiments differed from conditions
in viva in that the C3 concentration of the mixture corre-
sponded approximately to 20 units of B antigen/ml while
in patients with circulating C3NeF, the C3 level can be as
low as 1.5 B antigen units/ml.
These observations may explain the results of the studies
of Alper and Rosen [29] of C3 metabolism in membrano-
proliferative nephritis. These authors have reported that
the disappearance rate of radioactive iodine-labeled C3
given intravenously to hypocomplementemic patients with
membrano-proliferative nephritis is the same or only
slightly greater than in normal subjects. The results have
been interpreted as indicating that the low C3 levels of
these patients are to a large extent the result of diminished
synthesis of this component. It is apparent, however, that
diminished synthesis is not the only change occurring in
C3 metabolism. The reduced levels of C3 proactivator and
of late reacting complement components (Fig. 2) suggest
that C3 activation is occurring and the presence of circulat-
ing alpha 2D [30, 31], unique to hypocomplementemie
patients, must be accounted for.
A fact to be considered in interpreting the results of the
isotope studies is that in these patients the concentration
of C3, which would be very minimally increased by the
injection of radio-labeled C3, is in a range (1.5 B antigen
units/ml or more) in which accelerated breakdown by the
C3NeF system does not occur. From the in vitro studies
it seems likely that if in the experiments of Alper and Rosen
[29] large quantities of unlabeled C3 had been given
intravenously with the labeled C3 so that the serum C3
levels were increased toward the normal range, the dis-
appearance rate of the radio-label would have been
accelerated. In this event, the hypocomplementemic
patient could be said to have the potential for markedly
accelerated C3 breakdown but in the steady state at the C3
concentration existing in viva the catabolic rate would not
be expected to be great and the low serum level may reflect
to a large extent a low synthetic rate. If increased catabolism
is not occurring, one must account for the fact that the C3
breakdown product, alpha 2D, is demonstrable in viva in
severely hypocomplementemic patients and is not present
in the normal subject [30, 31]. The explanation probably
lies in the fact that the C3NeF reaction accounts for the
majority of the breakdown occurring in the hypocomple-
mentemic patient, a reaction that has as its by-product
alpha 2D. in the normal subject, on the other hand, C3
catabolism occurs by a different mechanism which does not
activate the molecule as does the C3NeF reaction and
which does not result in the entrance of alpha 2D into the
circulation.
At present the origin and nature of the nephritic factor
is not known. It is not of renal origin in that patients with
membrano-proliferative nephritis maintained on peritoneal
dialysis after bilateral nephrectomy continue to have high
C3NeF levels, low C3 levels and significant amounts of
alpha 2D in the circulation. There is evidence that C3NeF
is an IgG3. Thompson [271, employing column chromato-
graphy of the serum of several hypocomplementemic
patients with membrano-proliferative nephritis, found high
C3 converting activity in the eluates of DEAB columns
which by analysis contained only IgG. In these eluates, up
to 55 % of the IgG was IgG3. Treatment of the eluate with
insolubilized rabbit anti-human IgG removed the C3
converting ability. The converting ability was inhibited by
EDTA in the mixture and by heat inactivation of the normal
serum to which it was added. In subsequent work, Thomp-
son has shown that the TgG3 levels in the serum of patients
with membrano-proliferative nephritis are higher relative
to the total IgG level than in normal subjects [32]. IgG3
levels were also relatively higher in patients with low
serum complement levels than in those with normal comple-
ment levels or in those with lupus nephritis or other renal
diseases. However, high 1g03/IgG ratios were found in
four hypocomplementemic patients with acute post-
streptococcal nephritis, a disease in which C3NeF has not
been detectable. A high ratio was also found in two
mothers of children with membrano-proliferative nephritis
although they apparently manifested no evidence of renal
disease. It is apparent that although these observations are
of great interest and suggest that C3NeF is a unique
immunoglobulin, a number of questions are yet to be
answered.
The role of the C3NeF system in producing the glomerulo-
nephrtitis is not known. There is no well defined correlation
between the C3NeF [261 or C3 (24, 25) levels and progress
of the disease. Although C3NeF levels fall in response to
steroid therapy and C3 levels rise (25), such therapy
produces no dramatic change in the clinical course of the
patients. In theory if the C3NeF reaction occurred in
glomerular capillary walls, the resultant activation of the
terminal components of complement would produce an
inflammatory reaction. The only basis for implying a more
intensive C3NeF reaction in the glomerulus than elsewhere
is the fact that properdin is present in the glomerular
capillary walls [33]. If it could be shown that properdin is
involved in the C3NeF reaction, as is apparently the case
with activation of the alternate pathway by other substances
[15, 16], its position in the glomerulus might imply more
extensive C3 activation at that site. Serum properdin
levels have been shown to he somewhat reduced in patients
with membrano-proliferative nephritis [6]. However,
properdin is also found in the glomerulus and in markedly
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reduced concentration in the serum in acute post-strepto-
coccal nephritis [6, 33], a disease in which evidence of
alternate pathway activation is so far lacking.
In summary, the hypocomplementemia in membrano-
proliferative nephritis is produced by alternate pathway
activation by a circulating factor designated the C3 nephritic
factor. Evidence for this pathway of activation is the
characteristic complement profile in this disease, the
requirement for C3 proactivator for the nephritic factor
reaction in vitro, the observation that serum proactivator
levels are reduced in membrano-proliferative nephritis and
inversely related to C3NeF levels and the demonstration
of a shift of proactivator from the beta to the gamma
position on incubation of mixtures of serum from patients
with membrano-proliferative nephritis and normal serum.
The origin of the C3 nephritic factor is not known. It may
be found in abundance in patients with membrano-
proliferative nephritis who have been rendered anephric.
There is suggestive evidence that the nephritic factor is an
IgG3 and IgG3 levels have been found to be unusually
elevated in patients with this form of nephritis. The rate
of C3 breakdown by the C3NeF system varies directly
with the C3 level. At the very low C3 levels often encountered
in this disease, it is unlikely that accelerated breakdown
of C3 is occurring. This may account for the normal
catabolic rate of injected radio labeled C3 observed by
others. The clinical course of membrano-proliferative
nephritis cannot be correlated with the C3NeF or C3 levels
and the role of C3NeF in producing the glomerular inflam-
mation is not known. Steroid therapy has been shown to
raise C3 and lower C3NeF levels but does not have a
dramatic effect on the course of the disease. Serum properdin
levels tend to be low in this disease and properdin may be
demonstrated in glomerular capillary walls but there is as
yet no evidence that it has a role in producing the disease
or that it is involved in the C3NeF reaction.
Acute post-streptococcal nephritis
Details of the mechanism by which glomerular inflamma-
tion is produced in acute post-streptococcal nephritis
(AGN) are lacking and even less is known of the mechanism
producing the hypocomplementemia. The complement
profile in acute post-streptococcal nephritis is unique. It is
not strictly compatible with either classical or alternate
pathway activation. Serum levels of Cl and Clq are
usually normal. Observations on 21 patients reported by
various authors [5—7] have revealed only four with reduced
levels of Cl measured hemolytically or as Clq protein.
The reduction in three of these four was very slight. There
also appears to be less reduction of C4 and C2 levels in
acute nephritis than in lupus nephritis. Hemolytically
measured C4 was reduced in all three patients studied by
Gewurz et al [6], and in our laboratory the level of C4
protein measured immunologically has been found to be
consistently reduced early in the disease and to come into
the normal range before a normal C3 level is attained. On
the other hand, reduced C4 levels were seen in only six of
20 patients studied by Kohier and Bensel [5] and by Lewis,
Carpenter and Schur [7]. It is possible that the specimens
with normal levels were obtained some time after onset.
Measurements of functional C2 by Gewurz et a! [6] have
shown the levels to be only moderately reduced as compared
to the marked reduction in active lupus nephritis. In
contrast to the small and transient effect of the disease on
Cl, C4 and C2 levels, C3 levels are markedly reduced in
most patients. It would appear that the reaction depleting
the serum of C3 is also activating it in that C5 levels are
also significantly low early in the disease [5]. A plot of CS
levels versus C3 levels in AGN is shown in Fig. 2.
There has been little evidence of a circulating complement
reactive factor in hypocomplementemic patients with acute
nephritis. Several years ago Pickering, Gewurz and Good
[34] observed that addition of serum from patients with
AGN to guinea pig serum caused a reduction in the func-
tional activity of the terminal components (C3—9) of
guinea pig complement. However, the component or
components primarily affected were not determined and
the mechanism responsible for the anticomplementary
effect was not identified. In our hands a factor causing
C3 breakdown or activation comparable to the C3 nephritic
factor has not been demonstrable in the serum of patients
with acute nephritis and such serum is devoid of material
reacting with Clq in vitro [10]. In addition, as shown in
Fig. 3, serum C3 proactivator levels are normal in acute
nephritis and no shift in the mobility of the C3 proactivator
is demonstrable after incubation of a mixture containing
NHS and serum of hypocomplementemic patients with
L.)
flg. 3. The effect of acute post-streptococcal nephritis on serum
C3, C3 proactivator and properdin levels. Although this patient
had very little hematuria, the nephritis was otherwise typical.
Proteinuria was present in 4+ amounts initially and in trace
amounts by the 37th day. There was a 4.5 kg weight loss in the
first six days after admission and blood pressure was initially
120 mmHg diastolic. The dashed line indicates the lower limit
of the normal range for all three proteins.
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AGN. Thus, in contrast to the hypocomplementemia in
lupus nephritis and membrano-proliferative nephritis, there
is little evidence for a circulating complement reactive
factor or for alternate pathway activation.
An observation of interest is that a small number of the
patients with acute post-streptococcal nephritis have
normal C3 levels. In a series reported by Tina et al [35],
seven of 25 patients had normal C3 levels seven to 25 days
after onset of symptoms and in a series to be reported
from this laboratory (Strife, C. F., McAdams, A. J.,
McEnery, P. T., Bove, K. B. and West, C. D., in manu-
script), 20 of 182 patients have had normal levels two to
nine days after onset. In the latter series, the clinical course
and laboratory observations in the normocomplementemic
and hypocomplementemic groups were very similar.
There was equal evidence for antecedent streptococcal
infection in the two groups and both groups had patients
with both mild and severe disease. Light as well as electron
microscopy of the biopsies of five patients in each group
showed the typical morphology of acute nephritis. By
immunofluorescence, IgG could not be demonstrated in
any of the glomeruli from hypocomplementemic patients
but was consistently present in those from normocomple-
mentemic patients. Judging from the experience of Michael
et al [36] and Fish et al [37], this difference could conceiv-
ably have arisen by chance. All patients in both groups
appeared to have a benign disease which, as is typical in
childhood, resolved completely. An unexplained difference
was that the normocomplementemic patients had lower
serum levels of albumin and higher levels of cholesterol
than those in the hypocomplementemic group. This
difference aside, the observations suggest that the differing
behavior of C3 in the two groups was attributable to a
difference in host response. The observations also suggest
that the mechanism responsible for the low C3 levels in
acute nephritis may not be related to that which produces
the glomerulitis.
Recent observations which should be considered in a
discussion of the hypocomplementemia of AGN are those
dealing with properdin. Serum properdin activity was found
by Gewurz et al [6] to be markedly and consistently de-
creased in patients with acute post-streptococcal nephritis.
This observation has been confirmed by studies in our
laboratory employing an immunological method of mea-
surement of properdin. As shown in Fig. 3, not only are
the levels markedly reduced at the onset but in this patient,
as in a number of others followed serially, the levels were
found to come into the normal range much more slowly
than the C3 levels. Additional evidence that properdin is
involved in AGN comes from observations by Westberg
et al [33]. With the use of immunofluorescent studies em-
ploying monospecific antiserum, they found that properdin
is consistently present in the glomeruli in AGN. It is also
present in membrano-proliferative nephritis and occasional-
ly in lupus nephritis. The distribution of the properdin
corresponded to that of C3. These observations have also
been confirmed in our laboratory.
At present the significance of the low serum properdin
levels and of its presence in the glomeruli in acute post-
streptococcal disease is obscure. It is obviously possible
that the low serum levels reflect deposition in the glomeruli.
The slow return of the properdin levels to normal would
indicate that deposition continues long after the factor
affecting serum complement levels ceases to be effective or,
alternatively, that the synthesis rate of properdin is low.
It should, however, be noted that the serum levels of pro-
perdin in animals depleted of this protein returned to nor-
mal very quickly [16]. It is possible that the glomerular
deposition of properdin is the result of binding of properdin
to a complex polysaccharide present uniquely in the gb-
merulus in acute and membrano-proliferative nephritis. It
is intriguing to speculate that this complex, like poly-
saccharide-properdin complexes in vitro, causes local gb-
merular activation of the alternate pathway but there is
little evidence that the alternate pathway is activated in
AGN.
The peculiar complement profile, the inconclusive results
of studies to demonstrate circulating factors reactive with
complement, and the normal serum C3 proactivator levels
in AGN make it attractive to hypothesize that in this disease,
in contrast to lupus nephritis and membrano-proliferative
nephritis, the hypocompbementemia is produced by a com-
plement reaction occurring in the glomerulus rather than
in the circulation. There is much precedent for this assump-
tion. From Kellett's original observations [2], the concept
has been popular that the hypocomplementemia and gb-
merulitis which follows a streptococcal infection are the
result of deposition of complement-reactive immune com-
plexes in the walls of capillaries of the glomerulus as well
as of other tissues and organs. These complexes are thought
to be composed of antigen derived from the nephritogenic
streptococcus and homologous antibody. Support for this
concept is provided by immunofluorescent studies employ-
ing labeled antibody to various antigens of the streptococcus.
Seegal et al [38], using labeled antiserum to antigens of type
12, beta hemolytic streptococci observed fluorescence of the
glomeruli in seven of twelve patients with AGN and one of
three with chronic glomerulonephritis. Michael et al [36]
observed fluorescence in the gbomeruli of two of ten patients
with labeled antibody to type I, group A, beta hemolytic
streptococci. In both series, biopsies obtained within 12
days of onset were more often positive although in the
series of Seegal et al [38], positive results were obtained in
two patients 21 and 35 days after onset while in the series of
Michael et al [36], one at eight days was negative. Failure
to obtain positive results may be indicative that, with time,
antibody binding sites are not available for reaction with
labeled antibody or that the antigen disappears.
Additional support for the concept that immune com-
plexes containing streptococcal antigens are present in the
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lesion is provided by the observations of Treser Ct al [39].
These workers found that the TgG of patients with post-
streptococcal nephritis, when labeled with fluorescein,
would produce fluorescence of the patients' own glomeruli
or those of other patients with acute post-streptococcal
nephritis. The fluorescence was more intense if the biopsy
was performed within five days of the onset of the disease
and if the labeled IgG was derived from a serum specimen
obtained one week or more after onset. In this study, the
appropriate controls were negative. It could also be de-
monstrated that absorption of the labeled IgG with group
A, type 12, beta hemolytic streptococci or with the plasma
membrane of streptococci cultured from patients with
acute post-streptococcal nephritis markedly reduced the
intensity of the fluorescence.
The above observations are compatible with the concept
of an origin of the disease from an immune complex
derived from streptococcal antigen. Taken together they
suggest that within a week or so after onset, the antigen is
present in the glomeruli and has unreacted determinant
groups. With time these determinant groups are no longer
available to react with antibody. From the study of Treser
et al [39], it would appear that the titers of the circulating
antibody peak at some time after the first week of the disease.
Thus, early after onset there would be antigen excess in the
glomeruli and later, antibody excess.
This immune complex concept would lead to the pre-
diction that TgG should be regularly demonstrable in the
glomeruli of patients with AGN. In most series, however,
patients have been found who have no glomerular deposits
of IgG. In the series published by Michael et al [36], biopsies
of two of twelve patients taken within four weeks of onset
showed no labeling with anti-TgG and in two other patients
only trace amounts of IgG were demonstrable. Fish et al
[37] found eight of 15 biopsies obtained within the same time
period post-onset to be negative when reacted with labeled
antibody to IgG. Biopsies obtained later than four weeks
after onset rarely gave a positive reaction for IgG. There
was a trend for patients without demonstrable IgG early
after onset to have less severe disease than those with de-
monstrable immuno protein. In nearly all biopsies without
demonstrable IgG, C3 was demonstrable and relatively
plentiful. It is difficult to correlate these observations with
the concept that antigen excess is present early after onset
followed by antibody excess.
It is difficult to understand what endowment the nephri-
togenic streptococcus has which results in the formation of
relatively large amounts of complement-reactive complexes.
The endowment appears to be unique in that other strep-
tococci or organisms of other species do not produce this
reaction. A relatively minor infection with a nephritogenic
streptococcus which would seemingly provide little antigen
can produce a severe nephritis. In contrast, the nephritis
produced by a chronic bacteremia with a relatively non-
virulent organism such as is seen in subacute bacterial
endocarditis or "shunt" nephritis requires a long-standing
infection which supplies large amounts of antigen. In con-
trast to acute nephritis, the serum of patients with chronic
bacteremia and active nephritis contains complexes which
react with Clq in agar. Thus it is a nephritis which differs
in many respects from acute post-streptococcal nephritis.
It would appear that the nephritogenic streptococcus must
either contribute a very unique antigen or activate some
other mechanism.
In summary, there is evidence of glomerular immune
complex deposition in AGN, with the antigen being the
plasma membrane of the nephritogenic streptococcus. A
unique endowment of this antigen, as compared to antigens
of other bacteria, must be postulated to explain the often
severe glomerular inflammatory reaction produced. The
immune complex theory is, however, difficult to reconcile
with the frequent absence of glomerular deposits of EgG
by immunofluorescent techniques. In contrast to lupus
nephritis, attempts to identify complement reactive factors
in the plasma in AGN have given inconclusive results and
evidence of alternate pathway activation is lacking. It
seems possible that complement activation occurs only in the
glomerulus in this disease as compared to breakdown in
the circulation in other hypocomplementemic nephritides.
Serum properdin levels in acute nephritis are low and pro-
perdin deposits are present in glomerular capillary walls,
two observations which cannot as yet be related to either
the hypocomplementemia or the glomerulitis. Because
certain patients may have a normocomplementemic acute
nephritis which differs very little in etiology or in clinical
and laboratory characteristics from hypocomplementemic
nephritis, it seems possible that the mechanism producing
the hypocomplementemia in this disease is not intimately
related to that producing the nephritis. From the data at
hand, no unified concept satisfactorily explaining the hypo-
complementemia or the glomerulitis can be derived which
accounts for all of the observations.
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